Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem cell transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

NCT03530085

Acute Myeloid Leukemia Allogeneic Hematopoietic Stem Cell Transplantation Conditioning +1 more

UNKNOWN PHASE2/PHASE3

Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL

NCT02766868

Lymphoblastic Leukemia, Acute, Adult

UNKNOWN PHASE2

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT05674539

Acute Myeloid Leukemia, Adult Myelodysplastic Syndrome(MDS) Allogeneic Hematopoietic Stem Cell Transplantation

ENROLLING_BY_INVITATION PHASE3

Study on the Efficacy and Safety of MA-BUCY2 Conditioning in High-risk AML Patients Underwent Haplo-HSCT

NCT05814731

Haploidentical Stem Cell Transplantation Conditioning

NOT_YET_RECRUITING NA

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

NCT03412266

Myelodysplastic Syndromes

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia Myelodysplastic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

modified BuFlu, HSCT, elder/intolerable

The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.

modified BuFlu conditioning

Intervention Type PROCEDURE

The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

modified BuFlu conditioning

The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed of hematologic malignant disease
* will undergo HLA matced HSCT
* age \>=55years
* \<55year and intolerable to standard myeloablative conditioning